Companies › Vifor Pharma
1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 4, 1 Phase 3; Genitourinary, Metabolic and endocrine; next expected readout Dec 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Patiromer Potassium binder that exchanges potassium for calcium in the gastrointestinal tract | – | Phase 2 | Hyperkalemia; Chronic Kidney Diseases; Hyperkalaemia | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06858280 | Patiromer | Phase 3 | Hyperkalaemia | Genitourinary | Jul 2026 |
| NCT06256991 | Patiromer | Phase 4 | Chronic Kidney Diseases | Genitourinary | Dec 2026 |
| NCT05766839 | Patiromer | Phase 2 | Hyperkalemia | Metabolic and endocrine | Dec 2029 |
No annotated target.
–
Sparrow Pharmaceuticals Maze Therapeutics Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Housey Healthcare ULC
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.